Idenix Pharmaceuticals (IDIX) Now Up 73% This Week On Takeover Chatter
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Join SI Premium – FREE
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) is indicated to open higher for the third straight session following this weekend's takeover of Inhibitex (Nasdaq: INHX) by Bristol-Myers at a 163% premium, albeit modestly.
Takeover talk has been swirling around the company since the deal for its Hep-C peer. Investors say Idenix is the next obvious takeover target, along with Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN).
Shares of IDIX last traded at $12.22 in pre-open trading, up 1.8 percent. The stock is up 73 percent on the week.
Takeover talk has been swirling around the company since the deal for its Hep-C peer. Investors say Idenix is the next obvious takeover target, along with Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN).
Shares of IDIX last traded at $12.22 in pre-open trading, up 1.8 percent. The stock is up 73 percent on the week.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Motorola Solutions buys counter-drone firm D-Fend for $1.5B
- Terreno Realty buys Redmond, WA industrial property for $8M
Create E-mail Alert Related Categories
RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
